Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacopeia Names New Software Unit, Launches Consulting Service

NEW YORK, April 2 – Pharmacopeia announced that it has merged its software subsidiaries into a new unit named Accelrys, which will begin operating as a separate unit on June 1.

The four subsidiaries, Molecular Simulations, Synopsys Scientific Systems, Oxford Molecular, and the Genetics Computer Group, had pro forma revenues of more than $90 million in 2000, or 76 percent of Pharmacopeia’s overall revenues of $119 million.

In addition, Pharmacopeia announced that Accelrys would also have a new group dedicated to providing consulting services.

Pharmacopeia of Princeton, NJ, said that the restructuring effort would allow the company, which also has a drug discovery business, to operate more efficiently.

"The scale of our new operation allows us to invest more effectively in our R&D and to develop services to be offered by our new consulting group," Michael Stapleton, chief operating officer of Accelrys, said in a statement. “Our vision is of an integrated software platform supporting enterprise-wide R&D decisions."

Accelrys will continue to offer a range of software tools for simulation, bioinformatics, cheminformatics, workflow management, and decision support. The new unit, which will also help to support Pharmacopeia’s drug discovery efforts, will also offer consulting services.

"This new, highly skilled team is the best way to meet the unique needs of our clients," said Robert White, senior vice president of sales and consulting services at Accelrys. "Consulting services is a great team of expert scientists and software engineers who understand customers' businesses and research processes, and work with them to develop solutions tailored to their requirements and corporate systems."

Accelrys, which has more than 500 employees, will be based in San Diego and Cambridge, UK.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.